Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-alpha-2a/Ribavirin Therapy
| Autor: | Aysel Caglar, Murat Ozkaya, Umit Seza Tetikkurt, Betul Tas, Kamuran Turker, Ebru Tas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Anagen effluvium
medicine.medical_specialty Combination therapy Hepatitis C virus Case Report medicine.disease_cause Telogen effluvium chemistry.chemical_compound Interferon medicine Hepatology integumentary system business.industry Ribavirin Alopecia Alopecia areata medicine.disease Dermatology Infectious Diseases chemistry Rheumatoid arthritis Therapy Chronic Hepatitis C medicine.symptom business medicine.drug |
| Zdroj: | Hepatitis Monthly |
| ISSN: | 2582-1474 |
| Popis: | WOS: 000352233600005 PubMed: 25821474 Introduction: Various types of dermatological manifestations have been reported due to hepatitis C virus (HCV) infection and anti-HCV therapy. Some of them have been described during IFN-based therapies. PEG-IFN-alpha-2a/RBV combination is used as the international standard of treatment for HCV infection for a long time. The combination therapy yields an adverse-event profile similar to standard interferon (IFN) therapy. Some of these adverse effects are rheumatologic, neuropsychiatric and dermatological manifestations including alopecia. Case Presentation: We reported a 43-year-old woman with dystrophic anagen effluvium (DAE), rheumatoid arthritis and Hashimoto thyroiditis, which were developed under the combination therapy for chronic HCV infection. Conclusions: Although some cases of alopecia areata (AA) and telogen effluvium (TE) were reported in literature, no case of DAE associated with PEG-INF-alpha-2a/RBV combination therapy was reported previously. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|